Stomach pain on Foundayo™

Abdominal pain in the label and the official record

Foundayo™ is a once-daily tablet of orforglipron, a GLP-1 receptor agonist, approved in the US for weight management ^[1]. Its Table 1 pools Trials 1 and 2, known as ATTAIN-1 and ATTAIN-2, in which 3,155 adults took Foundayo™ for up to 72 weeks. The table only shows reactions seen in at least 5% of treated people and more often than on placebo, and the abdominal pain row carries a footnote: it includes other related terms ^[1]. The Medication Guide lists stomach (abdominal) pain among the most common side effects ^[2].

Outside the US the record is thinner. The European Medicines Agency’s committee gave a positive opinion on 15 October 2026 for weight management and type 2 diabetes, but there is no EMA product information yet, so no European frequency band exists ^[3]. Health Canada’s drug database has no entry for Foundayo™ or orforglipron ^[4].

Two registry rows instead of one

The trials ran on an investigational formulation; the label translates their 6, 12 and 36 mg doses into Foundayo™ 5.5, 9 and 17.2 mg ^[1]. On ClinicalTrials.gov, each trial lists events by standard medical terms, and pain in the belly appears under two names: abdominal pain and upper abdominal pain ^[5][6]. They should not be added together. One person can appear under both, and the label’s grouping may take in further terms, so neither the sum nor a single row equals the label figure. Both ATTAIN trials and ACHIEVE-3 posted only events that reached 5% in at least one group ^[5][6][7].

Reading the registry figures

• In both weight trials, each pain term was roughly twice as common on orforglipron as on placebo, without a steady climb from the lowest to the highest dose ^[5][6].
• In ATTAIN-2, upper abdominal pain on 36 mg (3.7%) was close to placebo; with about 320 people per group, a gap of that size can be chance ^[6].
• ACHIEVE-3 does not list upper abdominal pain at all. That means no group reached 5%, not that nobody had it ^[7].
• ACHIEVE-3 was open label, so people knew which tablet they took, which can shape what gets reported. It also enrolled people with type 2 diabetes, a use the US label does not cover ^[1][7].

Severity and timing

Among people on Foundayo™ who had any stomach or bowel reaction, 60% described it as mild, 36% as moderate and 4% as severe ^[1]. The label says nausea, vomiting and diarrhoea were more frequent while the dose was being raised and became less frequent later; it does not make that statement for abdominal pain ^[1]. The ATTAIN-2 publication reports that stomach and bowel events occurred mainly during dose escalation ^[8].

The label starts at 0.8 mg and allows each step only after at least 30 days, a pace meant to reduce stomach and bowel reactions ^[1]. Even so, stomach and bowel reactions led 3% to 6% of people on Foundayo™ to stop, against 0.7% on placebo, and severe reactions of this kind were seen in about 3% against 1% ^[1]. The label advises against the tablet in severe gastroparesis, a condition in which the stomach empties very slowly ^[1].

Why a GLP-1 tablet can make the belly ache

• From the label: Foundayo™ slows stomach emptying, most after the first dose and less over time, and it reduces food intake, likely by lowering appetite ^[1]. The label does not tie abdominal pain to either effect by name.
• Suggested but not measured: constipation, gas and a swollen belly are also listed reactions ^[1], and MedlinePlus counts constipation and gas among the common, less serious causes of belly pain ^[9]. No orforglipron study has tested how much of the pain comes through these routes.
• General medical knowledge: belly pain can come from the gallbladder, pancreas, liver, kidneys or bowel, and its location is a key clue to the organ involved ^[10].

Four kinds of pain the label handles separately

Blood tests can add a confusing signal: pancreatic amylase rose by 16% to 20% and lipase by 26% to 31% on average, against 3% and 4% on placebo, with unknown meaning in the absence of other signs of pancreatitis ^[1], and a network meta-analysis of orforglipron trials found raised enzymes without matching clinical events ^[11].

• Pancreatitis (section 5.2): persistent or severe abdominal pain, sometimes radiating to the back, with or without nausea or vomiting. If it is suspected, the label says to stop Foundayo™; six people on the tablet and one on placebo had confirmed cases in the pooled trials ^[1]. Our Foundayo™ pancreatitis page covers those cases.
• Gallbladder disease (section 5.8): the Medication Guide describes pain in the upper stomach, fever, yellowing of the skin or eyes and clay-coloured stools ^[2]. Gallstones were reported in 1% against 0.7% on placebo and the label links these events to weight reduction ^[1]; our gallbladder page goes into detail.
• Severe stomach reactions (section 5.3): the Medication Guide wants your provider to hear about stomach trouble that is severe or persists ^[2]. Ongoing vomiting or diarrhoea also matters because fluid loss can harm the kidneys (section 5.4) ^[1].
• Bowel blockage (section 6.2): ileus, intestinal obstruction and severe constipation with faecal impaction have been reported after approval for GLP-1 receptor agonists as a class, without a known frequency ^[1]. The ATTAIN-2 registry lists one serious intestinal obstruction on 6 mg and one small-bowel obstruction on 12 mg, and none on placebo; single cases cannot show cause ^[6].

Other reasons for a sore belly

MedlinePlus lists constipation, irritable bowel syndrome, food intolerance such as lactose intolerance, food poisoning and stomach flu among the less serious causes, and appendicitis, kidney stones, ulcers, diverticulitis, hernia, urinary tract infection, reflux, endometriosis and severe menstrual cramps among the others ^[9]. Cleveland Clinic adds ovulation pain and notes that pain can be felt in the belly while starting in the chest, pelvis or back ^[10].

Intensity is a poor guide on its own: MedlinePlus notes that a stomach virus can hurt badly while early appendicitis may cause only mild pain ^[9]. Location, pattern and accompanying symptoms say more.

Easing a mild ache

For mild pain, MedlinePlus suggests sipping water or other clear fluids and holding off solid food for the first few hours. If the pain is high in the belly after meals, it says antacids may help and suggests avoiding citrus, fatty or fried food, tomato products, caffeine, alcohol and fizzy drinks ^[9]. To prevent some types of pain, it mentions smaller, more frequent meals, regular exercise, fewer gas-producing foods and enough fibre ^[9]. Cleveland Clinic adds gentle heat such as a warm water bottle ^[10].

MedlinePlus also says not to take any medicine for the pain without talking to your provider, and asks people with diabetes to check their blood sugar often ^[9]. With Foundayo™ there is a second reason to ask a pharmacist first: the tablet slows stomach emptying and can change how other oral medicines are absorbed ^[1].

Details specific to the tablet

Foundayo™ is taken once a day, with or without food, and swallowed whole ^[1]. After seven or more missed doses in a row, the label restarts escalation at a lower dose because of stomach side effects ^[1]. A new prescription can matter too: strong CYP3A4 inhibitors raise orforglipron levels and may increase its side effects, so the label caps the dose when they are used together ^[1]. If stomach pain started alongside a new medicine, mention both.

Foundayo™ is a trademark of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Eli Lilly and Company.